Entrada Therapeutics (TRDA) Total Current Liabilities (2020 - 2026)

Entrada Therapeutics' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $19.2 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 4.15% year-over-year to $19.2 million in Q1 2026; TTM through Mar 2026 was $19.2 million, a 4.15% increase from a year earlier, with the FY2025 full-year figure at $24.5 million, down 38.07% from the prior year.
• Total Current Liabilities declined to $19.2 million in Q1 2026 per TRDA's latest filing, from $24.5 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $173.9 million in Q1 2024 and bottomed at $15.4 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $24.5 million (2025), against an average of $67.7 million.
• Across the five-year window, Total Current Liabilities jumped 856.79% in 2023 and tumbled 89.4% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $22.0 million in 2022, then soared by 622.72% to $158.8 million in 2023, then sank by 75.14% to $39.5 million in 2024, then plunged by 38.07% to $24.5 million in 2025, then decreased by 21.5% to $19.2 million in 2026.
• Per Business Quant, the three latest TRDA Total Current Liabilities figures stand at $19.2 million (Q1 2026), $24.5 million (Q4 2025), and $24.0 million (Q3 2025).